Novartis AG (NVS) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
NVS
Novartis AGUSD
137.70
-13.94% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — NVS
No data in this window.
INDY NEWS coverage of NVS1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHNovartis Cholesterol Drug Failure Triggers Sector-Wide Biopharma Selloff
Novartis's failed trial for a cholesterol-lowering drug that targets Lp(a) sparked a broad selloff across biopharma stocks betting on the same cardiovascular strategy.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.